

Bergamo 02/03/2021

Dear editors and reviewers,

Reviewer:

There are many differences between HBV and HCV. For pediatric viral hepatitis, the selection of anti-virus drug is challenged because of many factors. This review show us the success of DAA on HCV and new development of drug concerning with HBV. According to clinic trails in children, more and more anti-virus drugs are accepted and significant benefits of treatment are reported. The author gives us a whole picture about promising anti-virus treatments for pediatric hepatitis B and C chronic infection.

Answer: Thank you.

Editor:

Thank you very much for the great opportunity of publishing our work on such an important journal as WJG.

We totally understand the self-citation policy of the Journal.

We cut a couple of citations involving co-authors of the manuscript, but we struggle to decrease their number to 10% or less and we sincerely would find this detrimental to the manuscript integrity and overall value, and thus ultimately for the reader.

Some of the authors are understandably eminent experts of the topic, and participated in some of the most authoritative papers in paediatric viral hepatitis, which is a rather rare condition, especially in Western countries.

We hope that the Editor could waive this request.

The enclosed figure is author's own work (made by Emanuele Nicastro). We cannot provide a Power point because the figure was realized with an online rendering program (www.biorender.com), we could transmit the right to modify the figure but all changes should be done in biorender.com.

Best regards

Dr. Emanuele Nicastro MD, PhD

Pediatric Hepatology Gastroenterology and Transplantation, ASST Papa Giovanni XXIII,
Bergamo, Italy